The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs

키워드

참고문헌 (115)

1. Furtado LFV, "Benzimidazole resistance in helminths : from problem to diagnosis", Acta Trop, 162, pp.95~102 (2016)
2. Friedman PA, "Interaction of anthelmintic benzimidazoles with Ascaris suum embryonic tubulin", Biochim Biophys Acta, 630, pp.271~278 (1980)
3. Cleeland CS, "Reducing the toxicity of cancer therapy : recognizing needs, taking action", Nat Rev Clin Oncol, 9, pp.471~478 (2012)
4. Tang Y, "Co-delivery of trichosanthin and albendazole by nano-self-assembly for overcoming tumor multidrug-resistance and metastasis", ACS Appl Mater Interfaces, 9, pp.26648~26664 (2017)
5. Dayan AD, "Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics", Acta Trop, 86, pp.141~159 (2003)
6. Lai SR, "In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells", Vet Comp Oncol, 15, pp.1445~1454 (2017)
7. Marslin G, "Solid lipid nanoparticles of albendazole for enhancing cellular uptake and cytotoxicity against U-87 MG glioma cell lines", Molecules, 22, pp.2040~ (2017)
8. Bai RY, "Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme", Neuro Oncol, 13, pp.974~982 (2011)
9. Kipper FC, "Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas", Invest New Drugs, 36, pp.323~331 (2018)
10. Markowitz D, "Microtubule-targeting agents can sensitize cancer cells to ionizing radiation by an interphase-based mechanism", Onco Targets Ther, 10, pp.5633~5642 (2017)
11. De Witt M, "Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors", Mol Med, 23, pp.50~56 (2017)
12. Larsen AR, "Repurposing the antihelmintic mebendazole as a hedgehog inhibitor", Mol Cancer Ther, 14, pp.3~13 (2015)
13. Skibinski CG, "Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma", J Neurooncol, 140, pp.529~538 (2018)
14. Michaelis M, "Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen", Sci Rep, 5, pp.8202~ (2015)
15. Liu H, "18F-FDG PET imaging for monitoring the early anti-tumor effect of albendazole on triple-negative breast cancer", Breast Cancer, 27, pp.372~380 (2020)
16. Zhang L, "Mebendazole potentiates radiation therapy in triple-negative breast cancer", Int J Radiat Oncol Biol Phys, 103, pp.195~207 (2019)
17. Oh E, "Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition", Int J Cancer, 143, pp.1978~1993 (2018)
18. Zhang L, "Systems biology-based discovery of a potential Atg4B agonist(Flubendazole)that induces autophagy in breast cancer", Mol Biosyst, 11, pp.2860~2866 (2015)
19. Hou ZJ, "Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells", Oncotarget, 6, pp.6326~6340 (2015)
20. Kim YJ, "Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer", Cancer Lett, 412, pp.118~130 (2018)
21. anti-neoplastic cytotoxicity in dual combination with mebendazole against chemotherapeutic-resistant mammary adenocarcinoma, "J Clin Exp Oncol", 2013, 1000109~
22. Belaz KR, "Enantiomeric resolution of albendazole sulfoxide by semipreparative HPLC and in vitro study of growth inhibitory effects on human cancer cell lines", J Pharm Biomed Anal, 66, pp.100~108 (2012)
23. Mrkvová Z, "Benzimidazoles downregulate Mdm2 and MdmX and activate p53 in MdmX overexpressing tumor cells", Molecules, 24, pp.2152~ (2019)
24. Zanganeh S, "Electrochemical approach for monitoring the effect of anti tubulin drugs on breast cancer cells based on silicon nanograss electrodes", Anal Chim Acta, 938, pp.72~81 (2016)
25. Shashaani H, "Silicon nanowire based biosensing platform for electrochemical sensing of Mebendazole drug activity on breast cancer cells", Biosens Bioelectron, 85, pp.363~370 (2016)
26. Taranejoo S, "Dual effect of F-actin targeted carrier combined with antimitotic drug on aggressive colorectal cancer cytoskeleton : allying dissimilar cell cytoskeleton disrupting mechanisms", Int J Pharm, 513, pp.464~472 (2016)
27. Priotti J, "Repositioning of anti-parasitic drugs in cyclodextrin inclusion complexes for treatment of triple-negative breast cancer", AAPS PharmSciTech, 19, pp.3734~3741 (2018)
28. Duan Q, "Use of fenbendazole-containing therapeutic diets for mice in experimental cancer therapy studies", J Am Assoc Lab Anim Sci, 51, pp.224~230 (2012)
29. Duan Q, "Fenbendazole as a potential anticancer drug", Anticancer Res, 33, pp.355~362 (2013)
30. Spagnuolo PA, "The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from Vinca alkaloids and displays preclinical activity in leukemia and myeloma", Blood, 115, pp.4824~4833 (2010)
31. Králová V, "Antiproliferative effect of benzimidazole anthelmintics albendazole, ricobendazole, and flubendazole in intestinal cancer cell lines", Anticancer Drugs, 24, pp.911~919 (2013)
32. Hanušová V, "The effect of flubendazole on adhesion and migration in SW480 and SW620 colon cancer cells", Anticancer Agents Med Chem, 18, pp.837~846 (2018)
33. Králová V, "Flubendazole induces mitotic catastrophe and senescence in colon cancer cells in vitro", J Pharm Pharmacol, 68, pp.208~218 (2016)
34. Lin S, "Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy", J Exp Clin Cancer Res, 38, pp.293~ (2019)
35. Williamson T, "Mebendazole and a non-steroidal anti-inflammatory combine to reduce tumor initiation in a colon cancer preclinical model", Oncotarget, 7, pp.68571~68584 (2016)
36. Ehteda A, "Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice", BMC Cancer, 13, pp.86~ (2013)
37. Ehteda A, "Complexation of albendazole with hydroxypropyl-β-cyclodextrin significantly improves its pharmacokinetic profile, cell cytotoxicity and antitumor efficacy in nude mice", Anticancer Res, 32, pp.3659~3666 (2012)
38. Dogra N, "Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells : a novel antiproliferative agent with a potential therapeutic implication", J Biol Chem, 287, pp.30625~30640 (2012)
39. Pourgholami MH, "Antitumor activity of albendazole against the human colorectal cancer cell line HT-29 : in vitro and in a xenograft model of peritoneal carcinomatosis", Cancer Chemother Pharmacol, 55, pp.425~432 (2005)
40. Zhang X, "Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis", Exp Ther Med, 13, pp.595~603 (2017)
41. Pinto LC, "The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model", Toxicol In Vitro, 29, pp.2038~2044 (2015)
42. Pinto LC, "Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line(AGP01)", Toxicol In Vitro, 60, pp.305~312 (2019)
43. Celestino Pinto L, "Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis", Toxicol In Vitro, 43, pp.87~91 (2017)
44. Ghasemi F, "Repurposing albendazole : new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer", Oncotarget, 8, pp.71512~71519 (2017)
45. Zhang F, "Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma(HNSCC)", Oncotarget, 8, pp.12968~12982 (2017)
46. Wang LJ, "Non-mitotic effect of albendazole triggers apoptosis of human leukemia cells via SIRT3", ROS, TTP axis-mediated TNF-α upregulation, pp.Biochem Pharmacol, 2019[DOI]
47. Li Y, "Mebendazole for differentiation therapy of acute myeloid leukemia identified by a lineage maturation index", Sci Rep, 9, pp.16775~ (2019)
48. Blom K, "The anticancer effect of mebendazole may be due to M1 monocyte", macrophage activation via ERK1, Immunopharmacol Immunotoxicol, pp.2017, 39[DOI]
49. Khalilzadeh A, "Epothilone-paclitaxel resistant leukemic cells CEM", dEpoB300 are sensitive to albendazole : Involvement of apoptotic pathways, 2007, pp.74, 407~414
50. Kang BS, "Exploring the preparation of albendazole-loaded chitosan-tripolyphosphate nanoparticles", Materials(Basel), 8, pp.486~498 (2015)
51. Younis NS, "Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma", Sci Rep, 9, pp.19095~ (2019)
52. Pourgholami MH, "In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole", Cancer Lett, 165, pp.43~49 (2001)
53. Shimomura I, "Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer", Cancer Lett, 451, pp.11~22 (2019)
54. Zhou F, "Albendazole inhibits HIF-1α-dependent glycolysis and VEGF expression in non-small cell lung cancer cells", Mol Cell Biochem, 428, pp.171~178 (2017)
55. Dogra N, "Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways", Sci Rep, 8, pp.11926~ (2018)
56. Sasaki J, "The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells", Mol Cancer Ther, 1, pp.1201~1209 (2002)
57. Mukhopadhyay T, "Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo", Clin Cancer Res, 8, pp.2963~2969 (2002)
58. Xu D, "The anthelmintic agent oxfendazole inhibits cell growth in non‑small cell lung cancer by suppressing c-Src activation", Mol Med Rep, 19, pp.2921~2926 (2019)
59. Patel K, "Albendazole sensitizes cancer cells to ionizing radiation", Radiat Oncol, 6, pp.160~ (2011)
60. Kralova V, "Flubendazole and mebendazole impair migration and epithelial to mesenchymal transition in oral cell lines", Chem Biol Interact, 293, pp.124~132 (2018)
61. Pillai K, "Super aqueous solubility of albendazole in β-cyclodextrin for parenteral application in cancer therapy", J Cancer, 8, pp.913~923 (2017)
62. Pourgholami MH, "Albendazole-cyclodextrin complex : enhanced cytotoxicity in ovarian cancer cells", Anticancer Res, 28, pp.2775~2779 (2008)
63. Noorani L, "Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model", J Nanobiotechnology, 13, pp.25~ (2015)
64. Pourgholami MH, "Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole", BMC Cancer, 10, pp.143~ (2010)
65. Pourgholami MH, "Albendazole : a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice", Clin Cancer Res, 12, pp.1928~1935 (2006)
66. uril-type molecular container enables systemic delivery of effective doses of albendazole for treatment of SK-OV-3 xenograft tumors, "Mol Pharm", 2016, 809~818
67. Chu SW, "Potent inhibition of tubulin polymerisation and proliferation of paclitaxel-resistant 1A9PTX22 human ovarian cancer cells by albendazole", Anticancer Res, 29, pp.3791~3796 (2009)
68. Florio R, "The benzimidazole-based anthelmintic parbendazole: a repurposed drug candidate that synergizes with gemcitabine in pancreatic cancer", Cancers(Basel), 11, pp.11~ (2019)
69. Chen H, "Albendazole suppresses cell proliferation and migration and induces apoptosis in human pancreatic cancer cells", Anticancer Drugs, 31, pp.431~439 (2020)
70. Rushworth LK, "Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment", Br J Cancer, 122, pp.517~527 (2020)
71. Chen Q, "Oxibendazole inhibits prostate cancer cell growth", Oncol Lett, 15, pp.2218~2226 (2018)
72. Zhang QL, "Antitumor effect of albendazole on cutaneous squamous cell carcinoma(SCC)cells", BioMed Res Int, 2019, pp.3689517~ (2019)
73. Čáňová K, "Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells", Toxicol In Vitro, 46, pp.313~322 (2018)
74. Doudican NA, "XIAP downregulation accompanies mebendazole growth inhibition in melanoma xenografts", Anticancer Drugs, 24, pp.181~188 (2013)
75. Simbulan-Rosenthal CM, "The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma", Oncotarget, 8, pp.12576~12595 (2017)
76. Li Y, "The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation", Cancer Lett, 459, pp.268~276 (2019)
77. Doudican N, "Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells", Mol Cancer Res, 6, pp.1308~1315 (2008)
78. Williamson T, "Mebendazole inhibits tumor growth and prevents lung metastasis in models of advanced thyroid cancer", Endocr Relat Cancer, 27, pp.123~136 (2020)
79. Martarelli D, "Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice", Cancer Chemother Pharmacol, 61, pp.809~817 (2008)
80. Sawanyawisuth K, "Effect of the antiparasitic drug mebendazole on cholangiocarcinoma growth", Southeast Asian J Trop Med Public Health, 45, pp.1264~1270 (2014)
81. 성소정, "Autophagy Is a Potential Target for Enhancing the Anti-Angiogenic Effect of Mebendazole in Endothelial Cells", Biomolecules & Therapeutics, 27(1), pp.117~125 (2019), 한국응용약물학회[DOI]
82. Hassanpour M, "Distinct role of autophagy on angiogenesis : highlights on the effect of autophagy in endothelial lineage and progenitor cells", Stem Cell Res Ther, 9, pp.305~ (2018)
83. Kardideh B, "Autophagy, cancer and angiogenesis : where is the link", Cell Biosci, 9, pp.65~ (2019)
84. Bhutia SK, "Autophagy : cancer's friend or foe", Adv Cancer Res, 118, pp.61~95 (2013)
85. Mandhair HK, "Molecular modulation of autophagy : New venture to target resistant cancer stem cells", World J Stem Cells, 12, pp.303~322 (2020)
86. Görgülü K, "The role of autophagy in pancreatic cancer : from bench to the dark bedside", Cells, 9, pp.1063~ (2020)
87. Tan Z, "Comprehensive modeling and discovery of mebendazole as a novel TRAF2-and NCK-interacting kinase inhibitor", Sci Rep, 6, pp.33534~ (2016)
88. Shitashige M, "Traf2-and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth", Cancer Res, 70, pp.5024~5033 (2010)
89. Walker JC, "microRNA-24a is required to repress apoptosis in the developing neural retina", Genes Dev, 23, pp.1046~1051 (2009)
90. Sun Y, "miR-204 inhibits invasion and epithelial-mesenchymal transition by targeting FOXM1 in esophageal cancer", Int J Clin Exp Pathol, 8, pp.12775~12783 (2015)
91. Rubin J, "Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing", Oncotarget, 9, pp.30805~30813 (2018)
92. Bai RY, "Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model", Clin Cancer Res, 21, pp.3462~3470 (2015)
93. Bai RY, "Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis", Neuro-oncol, 17, pp.545~554 (2015)
94. Choi EK, "Differential effect of intraperitoneal albendazole and paclitaxel on ascites formation and expression of vascular endothelial growth factor in ovarian cancer cell-bearing athymic nude mice", Reprod Sci, 18, pp.763~771 (2011)
95. Pourgholami MH, "Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer", Cancer Chemother Pharmacol, 65, pp.597~605 (2010)
96. Nygren P, "Drug repositioning from bench to bedside : tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer", Acta Oncol, 53, pp.427~428 (2014)
97. Dobrosotskaya IY, "Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma", Endocr Pract, 17, pp.e59~ (2011)
98. Morris DL, "Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers", high incidence of neutropenia, 2001, pp.61, 42~46
99. Malik K, "StatPearls" (2020), StatPearls Publishing StatPearls Publishing LLC
100. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, "Albendazole", National Institute of Diabetes and Digestive and Kidney Diseases, ~ (2012)
101. 홍성태, "Albendazole and Praziquantel: Review and Safety Monitoring in Korea", Infection and Chemotherapy, 50(1), pp.1~10 (2018), 대한감염학회
102. Pawluk SA, "A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole", Clin Pharmacokinet, 54, pp.371~383 (2015)
103. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, "Mebendazole", National Institute of Diabetes and Digestive and Kidney Diseases, ~ (2012)
104. Pantziarka P, "Repurposing drugs in oncology(ReDO)-mebendazole as an anti-cancer agent", Ecancermedicalscience, 8, pp.443~ (2014)
105. Capece BP, "Enantiomeric behaviour of albendazole and fenbendazole sulfoxides in domestic animals : pharmacological implications", Vet J, 181, pp.241~250 (2009)
106. Villar D, "Biologic effects of fenbendazole in rats and mice : a review", J Am Assoc Lab Anim Sci, 46, pp.8~15 (2007)
107. Gonzalez AE, "Oxfendazole : a promising agent for the treatment and control of helminth infections in humans", Expert Rev Anti Infect Ther, 17, pp.51~56 (2019)
108. Čáňová K, "Anthelmintic flubendazole and its potential use in anticancer therapy", Acta Med(Hradec Kralove), 60, pp.5~11 (2017)
109. Theodorides VJ, "Toxicologic and teratologic studies of oxibendazole in ruminants and laboratory animals", Am J Vet Res, 38, pp.809~814 (1977)
110. Al-Hadiya BM, "Parbendazole", Profiles Drug Subst Excip Relat Methodol, 35, pp.263~284 (2010)
111. Sánchez S, "Enhanced plasma and target tissue availabilities of albendazole and albendazole sulphoxide in fasted calves : evaluation of different fasting intervals", J Vet Pharmacol Ther, 23, pp.193~201 (2000)
112. Movahedi F, "Nanoformulations of albendazole as effective anticancer and antiparasite agents", Nanomedicine(Lond), 12, pp.2555~2574 (2017)
113. Morris DL, "Albendazole in hydatid disease--hepatocellular toxicity", Trans R Soc Trop Med Hyg, 81, pp.343~344 (1987)
114. Eckardt K, "Relative potency of albendazole and its sulfoxide metabolite in two in vitro tests for developmental toxicity : the rat whole embryo culture and the mouse embryonic stem cell test", Reprod Toxicol, 34, pp.378~384 (2012)
115. Navarro M, "Developmental toxicity in rat fetuses exposed to the benzimidazole netobimin", Reprod Toxicol, 13, pp.295~302 (1999)

관련 논문AI추천